Business Context and Reporting Period
Company: Intelligent Bio Solutions Inc. (INBS)
Filing Type: Form 8-K (Current Report)
Date of Report: May 12, 2023
Reporting Period: Events occurring on May 8, 2023, and May 9, 2023.
The Company entered into Convertible Loan Conversion Agreements with eight lenders regarding convertible debt held by its subsidiary, Intelligent Fingerprinting Limited (IFP). This action followed stockholder approval obtained on May 8, 2023, to convert the Company's Series C Convertible Preferred Stock.
Key Financial Metrics
This filing details a specific capital restructuring event rather than periodic financial performance. Consequently, standard metrics such as revenue, profit, cash flow, and operating margins are not reported in this document.
- Convertible Debt Balance: £1,360,761 (principal and accrued interest as of May 8, 2023).
- Debt Conversion: The entire outstanding balance was converted into equity.
- Equity Issued: 1,149,273 shares of Series C Preferred Stock were issued to lenders, which were immediately converted into 172,386 shares of the Company's common stock.
Material Changes Versus Prior Period
The primary material change is the elimination of the Company's guarantee obligation for the £1,360,761 convertible debt held by IFP. This liability was extinguished through the conversion into equity securities. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
Management Commentary: The conversion was automatic for six lenders, while two lenders exercised their option to convert at their discretion. The transaction was deemed effective as of May 9, 2023.
Regulatory Status: The issuance of Series C Preferred Stock and common stock is intended to be exempt from registration under Section 4(a)(2) of the Securities Act, Rule 506 of Regulation D, and/or Rule 901.
Risks and Contingencies: The filing does not explicitly list new risks or contingencies beyond the standard disclosure that the description of the Conversion Agreement is qualified by reference to the full text filed as Exhibit 10.1.
Investor Verification Checklist
- Verify the exact terms of the Convertible Loan Conversion Agreement in Exhibit 10.1.
- Confirm the impact of the 172,386 new common shares on total outstanding share count and potential dilution.
- Review the May 12, 2023, Special Meeting of Stockholders minutes regarding the approval of the Series C Preferred Stock conversion.
- Assess the removal of the £1,360,761 debt guarantee from the Company's balance sheet liabilities.